These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18400115)

  • 1. Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement.
    McCabe C; Claxton K; O'Hagan A
    Int J Technol Assess Health Care; 2008; 24(2):140-5. PubMed ID: 18400115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative effectiveness and the European pharmaceutical market.
    Jönsson B
    Eur J Health Econ; 2011 Apr; 12(2):97-102. PubMed ID: 21267624
    [No Abstract]   [Full Text] [Related]  

  • 6. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.
    Tsoi B; Masucci L; Campbell K; Drummond M; O'Reilly D; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):497-511. PubMed ID: 23977976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands.
    Bijlmakers L; Jansen M; Boer B; van Dijk W; Groenewoud S; Zwaap J; Helderman JK; van Exel J; Baltussen R
    Value Health; 2020 Jan; 23(1):32-38. PubMed ID: 31952671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective.
    Hillock NT; Merlin TL; Karnon J; Turnidge J; Eliott J
    Int J Technol Assess Health Care; 2020 Nov; 37():e28. PubMed ID: 33138869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
    Wallerstedt SM; Henriksson M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a functional definition of a "rare disease" for regulatory authorities and funding agencies.
    Clarke JT; Coyle D; Evans G; Martin J; Winquist E
    Value Health; 2014 Dec; 17(8):757-61. PubMed ID: 25498770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?
    Hill S; Freemantle N
    Pharmacoeconomics; 2003; 21(11):761-7. PubMed ID: 12859218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.
    van Nooten F; Holmstrom S; Green J; Wiklund I; Odeyemi IA; Wilcox TK
    Drug Discov Today; 2012 Jun; 17(11-12):615-22. PubMed ID: 22366662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lag from FDA approval to published cost-utility evidence.
    Chambers JD; Thorat T; Pyo J; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health technology assessment. The pharmaceutical industry perspective.
    Schubert F
    Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 19. Better defining target populations for drugs with a view to reimbursement.
    Massol J; Boissel JP
    Therapie; 2014; 69(3):235-7. PubMed ID: 24927505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
    Lipska I; McAuslane N; Leufkens H; Hövels A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.